PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice

Area of Science:

• Endocrinology
• Metabolic Diseases
• Nephrology

Background:

• Peroxisome proliferator-activated receptor alpha (PPARalpha) regulates lipid and glucose metabolism.
• Type II diabetes mellitus is associated with significant renal complications.
• Understanding PPARalpha's role in diabetic nephropathy is crucial for therapeutic development.

Purpose of the Study:

• To investigate the therapeutic potential of fenofibrate, a PPARalpha activator, in ameliorating type II diabetes and its associated renal complications.
• To determine the effects of fenofibrate on hyperglycemia, insulin resistance, and kidney damage in a mouse model.

Main Methods:

• Male C57 BLKS db/db mice and controls were fed either a regular diet or a diet containing fenofibrate for 8 weeks.
• Key metabolic parameters including blood glucose, HbA1c, insulin levels, and body weight were monitored.
• Renal function was assessed by measuring urinary albumin excretion and examining kidney tissue for glomerular hypertrophy and mesangial matrix expansion.
• In vitro studies assessed fenofibrate's effect on type I collagen production in cultured mesangial cells.

Main Results:

• Fenofibrate treatment significantly reduced fasting blood glucose and HbA1c levels in diabetic mice.
• Amelioration of insulin resistance, decreased plasma insulin, reduced food intake, and slight body weight reduction were observed.
• Fenofibrate treatment markedly decreased pancreatic islet hypertrophy and increased insulin content.
• Urinary albumin excretion was significantly reduced, accompanied by decreased glomerular hypertrophy and mesangial matrix expansion.
• Fenofibrate decreased type I collagen production in cultured mesangial cells.

Conclusions:

• Activation of PPARalpha by fenofibrate demonstrates significant therapeutic benefits for hyperglycemia, insulin resistance, and albuminuria in type II diabetes.
• Fenofibrate exhibits protective effects against glomerular lesions, suggesting a role in mitigating diabetic nephropathy.
• The findings support fenofibrate as a potential therapeutic agent for managing type II diabetes and its renal complications.